title: Bone metabolism during long-term treatment with imatinib.
authors.forename: Susannah
authors.initials: S
authors.lastname: O'Sullivan
authors.forename: Anne
authors.initials: A
authors.lastname: Horne
authors.forename: Diana
authors.initials: D
authors.lastname: Wattie
authors.forename: Fran
authors.initials: F
authors.lastname: Porteous
authors.forename: Greg
authors.initials: G
authors.lastname: Gamble
authors.forename: Peter
authors.initials: P
authors.lastname: Browett
authors.forename: Andrew
authors.initials: A
authors.lastname: Grey
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001549:Benzamides / Q000494:pharmacology* / Q000627:therapeutic use; D015415:Biomarkers; D015519:Bone Density; D001842:Bone and Bones / Q000187:drug effects* / Q000378:metabolism*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000494:pharmacology* / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D011743:Pyrimidines / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D015415:Biomarkers; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate